Research and development daily K drug double therapy to treat Hodgkin's lymphoma CR doubled

2020.11.20 Research and Development NEWS: Eden Pharmaceuticals announces positive results in VASCEPA® China Phase III clinical studies; Lilly Barrettini is authorized by the FDA to treat COVID-19 hospitalized patients; Baiji Shenzhou Shudan anti-indogen in China approved to prevent solid tumor bone metastasis and other causes of SRE...... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
(click on the title, read the original) CD30/CD16A dual-specific teticodes combined with K drug therapy R/R HL better than single drug therapy recently, Affimed announced that the evaluation of AFM13 joint Mercadon anti-PD The results of a clinical study of the treatment of relapsed or refractic Hodgkin's lymphoma (R/R HL) Ib have been published in the Journal of Hematology.
data show that AMF13 and Keytruda combined to obtain a higher objective remission rate than Keytruda single-drug treatment, especially a full remission rate (double).
100 million Teng Pharmaceuticals announced VASCEPA® China Phase III clinical research achieved positive results Yiteng Pharmaceuticals announced today, in Chinese mainland vaSCEPA ® (twenty carbon pentalete capsules) treatment of high glycelin The Phase III EDPC003R01 study in patients with triesteremia (≥500mg/dL) was completed, and the results were statistically significant, reaching the main therapeutic endpoint defined in clinical trial scenarios and showing similar safety to placebos.
19 (Xinhua) -- Alnylam's 3rd innovative RNAi therapy has been approved for sale in the European Union for the first time, and Alnylam Pharmaceuticals announced that the European Commission has granted RNAi's treatment drug Oxlumo (lumasiran) a license to treat primary oxalic acid urine in all ages.
Lilly Baritini is authorized by the FDA for emergency use to treat COVID-19 hospitalized patients 19, Lilly and Incyte announced that the U.S. FDA issued Baricitinib and Remdes ivir) Authorization for emergency use of combination therapy for the emergency use of suspected or confirmed COVID-19 adults and children (2 years of age or older) hospitalized patients who require assisted oxygen supply, invasive mechanical aeration, or in vitro pulmonary oxygenation.
The application for aducanumab for the drug aducanumab was accepted by the EMA on the 19th, Biogen and Eisai announced recently that the European Medicines Agency has confirmed the acceptance of the application for the listing of the experimental drug aducanumab for Alzheimer's disease and will review it in accordance with the standard schedule.
On the 20th, Baiji Shenzhou deshudon resistance in China was approved to prevent solid tumor bone metastasis and other causes of SRE20, Baiji Shenzhou announced that NMPA has approved Angarve ® (Deshu single anti-injection) for the prevention of solid tumor bone metastasis and multiple myeloma caused by bone-related events (SRE).
the Angarve ® developed by Amjin, which was authorized by Baiji Shenzhou in accordance with a global cancer strategy agreed earlier this year.
-step pharmaceutical benzodiaxane chloride tablets by the drug registration certificate 20, step-long pharmaceutical issued a notice that the wholly-owned subsidiary Shaanxi step-high recently received the Approval of the State Drug Administration issued on the benzodiacychloride tablets "drug registration certificate."
Ruitron bio-heterogeneous immunocellular therapy products were approved clinically on the 19th, Ruitron Bio announced that the company's allogeneic immunocellular therapy product RC1012 injection obtained the CDE clinical trial implied license, to develop adaptive disorders for: recurrence of difficult to treat acute myeloid leukemia.
Sound Pharmaceuticals introduced a new class of drugs approved clinically for gyrophs with high uric acidemia CDE publicity shows that the first class of new drugs declared by the first sound pharmaceutical industry SIM1909-13 tablets obtained two clinical trials implied license, intended to be developed for gypsum with high uric acidemia patients.
SIM1909-13 tablet is a small molecular innovation drug developed by JW Pharmaceutical of Korea to selectively inhibit uric acid transport proteins.
September 2019, Synsheng Pharmaceuticals acquired a clinical development and commercialization interest in China.
AstraZenelan vaccine protects older groups AstraZeneta and Oxford University, published in The Lancet.
the vaccine uses the adenovirus ChAdOx1 as a vector to express the prickly protein of the new coronavirus.
team has previously assessed its effectiveness among young people, and the study has expanded to a broader group, including those aged 70 and over.
in terms of tolerance, the vaccine appears to perform better in older groups.